Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation.
Wang L, Rodriguez-Ulloa A, Berlanga-Acosta J, et al. · Pharmaceuticals (Basel)
Chronic GHRP-6 administration reduced post-infarct ventricular remodeling and improved systolic function in a permanent coronary ligation model, consistent with cytoprotective and anti-fibrotic effects mediated through growth hormone secretagogue receptor signalling.
Investigated as a preclinical (rat coronary ligation) in the field of endocrine research. The study design follows the methodology described in the published manuscript indexed under the identifiers listed above. Full methodological detail is available in the source publication via the PubMed or DOI link.
Chronic GHRP-6 administration reduced post-infarct ventricular remodeling and improved systolic function in a permanent coronary ligation model, consistent with cytoprotective and anti-fibrotic effects mediated through growth hormone secretagogue receptor signalling.
Preclinical rodent model only; clinical translation, optimal dose, and long-term cardiovascular safety in humans remain undefined.
- · PubMed: PMID 41901314 ↗
- · PubMed Central: PMC13029777 ↗
- · DOI: 10.3390/ph19030468 ↗
- · PubMed search by title: pubmed.ncbi.nlm.nih.gov ↗
- · Google Scholar: scholar.google.com ↗